DCT

1:26-cv-00977

Eli Lilly Co v. DR Reddys Laboratories Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00977, D. Del., 08/06/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of Delaware because Defendants conduct systematic and continuous business in the state, including developing and distributing generic pharmaceutical products, and have purposefully availed themselves of the district by regularly engaging in patent litigation there.
  • Core Dispute: Plaintiff alleges that Defendants' filing of Abbreviated New Drug Applications (ANDAs) to market generic versions of the drugs Mounjaro® and Zepbound® (active ingredient tirzepatide) constitutes an act of infringement of ten of Plaintiff's patents covering the drug's composition of matter, its pharmaceutical formulation, and its methods of use.
  • Technical Context: The technology relates to tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, a novel class of medication for treating type 2 diabetes and obesity.
  • Key Procedural History: The lawsuit is a Hatch-Waxman action triggered by Defendants' submission of ANDAs No. 220663 and 220664, which contained Paragraph IV certifications asserting that Plaintiff's patents are invalid, unenforceable, or will not be infringed by the proposed generic products. Plaintiff filed this action within the 45-day statutory window after receiving Defendants' notice letters. All asserted patents are listed in the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (the "Orange Book").

Case Timeline

Date Event
2015-01-09 '780 Patent Priority Date
2016-10-25 '780 Patent Issue Date
2018-06-22 Priority Date for '820, '623, '755, '756, and '404 Patents
2018-07-23 Priority Date for '987, '382, '758, and '740 Patents
2022-05-13 FDA Approval for Mounjaro® (tirzepatide)
2022-06-14 '820 Patent Issue Date
2023-11-08 FDA Approval for Zepbound® (tirzepatide)
2024-03-05 '623 Patent Issue Date
2025-05-13 '987 Patent Issue Date
2025-07-01 '382 Patent Issue Date
2025-10-28 '755, '756, and '758 Patents Issue Date
2026-05-05 '740 Patent Issue Date
2026-05-19 '404 Patent Issue Date
2026-07-14 Defendants send Notice Letters regarding ANDA submissions
2026-07-15 Plaintiff receives Notice Letters
2026-08-06 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,474,780 - "GIP AND GLP-1 CO-AGONIST COMPOUNDS"

The Invention Explained

  • Problem Addressed: The patent addresses the need for improved treatments for type 2 diabetes mellitus (T2D), as existing therapies do not adequately control glycemic levels for many patients and may have undesirable side effects US 9,474,780 B2, col. 1:19-27
  • The Patented Solution: The invention is a class of peptide compounds that act as dual agonists for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors US 9,474,780 B2, col. 1:4-9 This dual-action mechanism aims to provide enhanced glycemic control and potential weight loss benefits over single-agonist therapies. The core compound, later known as tirzepatide, is a modified 39-amino-acid peptide engineered with non-natural amino acids and a fatty acid moiety to improve its stability and extend its half-life, making it suitable for less frequent dosing US 9,474,780 B2, col. 2:55-65 US 9,474,780 B2, claim 1
  • Technical Importance: This dual incretin-receptor agonist approach represented a novel mechanism of action for T2D and obesity, offering the potential for superior efficacy compared to existing single-pathway incretin mimetics.

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶55
  • Essential elements of independent claim 1 include:
    • A compound of Formula: YX1EGTFTSDYSIX2LDKIAQKAX3VQWLIAGGPSSGAPPPS
    • wherein X1 is Aib; X2 is Aib
    • K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(yGlu)a-CO-(CH2)b-CO2H wherein a is 1 to 2 and b is 10 to 20
    • X3 is Phe or 1-Nal
    • The C-terminal amino acid is optionally amidated as a C-terminal primary amide
    • or a pharmaceutically acceptable salt thereof Compl. ¶54
  • The complaint reserves the right to assert other claims Compl. ¶55

U.S. Patent No. 11,357,820 - "GIP/GLP1 AGONIST COMPOSITIONS"

The Invention Explained

  • Problem Addressed: The patent addresses the need for a stable pharmaceutical composition of tirzepatide that provides an acceptable patient injection site experience US 11,357,820 B2, col. 1:23-29 Certain common pharmaceutical excipients, like citrate, can cause pain or stinging upon subcutaneous injection US 11,357,820 B2, col. 4:11-14
  • The Patented Solution: The patent discloses a specific aqueous formulation for tirzepatide comprising the active ingredient, sodium chloride (NaCl) as a tonicity-adjusting agent, and dibasic sodium phosphate as a buffering agent US 11,357,820 B2, abstract US 11,357,820 B2, col. 1:30-34 This combination is described as providing both commercially acceptable shelf-life and in-use stability while being associated with an acceptable patient experience upon injection US 11,357,820 B2, col. 1:16-19
  • Technical Importance: Developing a stable, injectable formulation that is well-tolerated by patients is critical for drugs intended for chronic, self-administered use, as poor tolerability can negatively impact patient compliance.

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶72
  • Essential elements of independent claim 1 include:
    • A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof;
    • NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; and
    • dibasic sodium phosphate Compl. ¶71
  • The complaint reserves the right to assert other claims Compl. ¶72

U.S. Patent No. 11,918,623 - "GIP/GLP1 AGONIST COMPOSITIONS"

  • Technology Synopsis: This patent claims a method of treating obesity by administering a specific pharmaceutical composition of tirzepatide. The composition is defined by concentration ranges for tirzepatide, dibasic sodium phosphate, NaCl, and optionally phenol Compl. ¶88
  • Asserted Claims: At least independent claim 1 Compl. ¶89
  • Accused Features: Defendants' proposed labeling for its generic Zepbound® product (ANDA No. 220664), which allegedly "instructs and encourages treating obesity" with the claimed composition Compl. ¶¶86-89

U.S. Patent No. 12,295,987 - "METHODS OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES"

  • Technology Synopsis: This patent claims a method of treating type 2 diabetes using a specific four-step dose-escalation regimen. The method is defined by administering doses that are about 25%, 50%, and 75% of a fourth dose, with specific criteria for the peptide's potency ratio Compl. ¶106
  • Asserted Claims: At least independent claim 1 Compl. ¶107
  • Accused Features: Defendants' proposed labeling for its generic Mounjaro® product (ANDA No. 220663), which allegedly "instructs and encourages treating type 2 diabetes" using the claimed dosing regimen Compl. ¶¶104-107

U.S. Patent No. 12,343,382 - "METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY"

  • Technology Synopsis: This patent claims methods of treating type 2 diabetes (claim 1) and improving weight management (claim 11). The methods involve administering an "escalation dose" from one group of specific dosages and a "maintenance dose" from another group of specific dosages Compl. ¶¶124 Compl. ¶126
  • Asserted Claims: At least independent claims 1 and 11 Compl. ¶125 Compl. ¶127
  • Accused Features: Defendants' proposed labeling for its generic Mounjaro® (ANDA No. 220663) and Zepbound® (ANDA No. 220664) products, which allegedly instructs and encourages the claimed treatment regimens Compl. ¶¶122-127

U.S. Patent No. 12,453,755 - "GIP/GLP1 AGONIST COMPOSITIONS"

  • Technology Synopsis: This patent claims a method of treating diabetes by administering a pharmaceutical composition with specific concentration ranges for tirzepatide, dibasic sodium phosphate, NaCl, and optional phenol Compl. ¶146
  • Asserted Claims: At least independent claim 1 Compl. ¶147
  • Accused Features: Defendants' proposed labeling for its generic Mounjaro® product (ANDA No. 220663), which allegedly "instructs and encourages treating diabetes" with the claimed composition Compl. ¶¶144-147

U.S. Patent No. 12,453,756 - "GIP/GLP1 AGONIST COMPOSITIONS"

  • Technology Synopsis: This patent claims a pharmaceutical composition comprising tirzepatide, a specific range of NaCl, and having a pH between 6.5 and 7.5 Compl. ¶164
  • Asserted Claims: At least independent claim 1 Compl. ¶165
  • Accused Features: The formulation of Defendants' proposed generic Mounjaro® and Zepbound® products Compl. ¶165

U.S. Patent No. 12,453,758 - "METHODS OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES"

  • Technology Synopsis: This patent claims a method for improving weight management using a four-step dose-escalation regimen, similar to the '987 Patent but defined by different potency ratio boundaries related to different SEQ ID NOs Compl. ¶181
  • Asserted Claims: At least independent claim 1 Compl. ¶182
  • Accused Features: Defendants' proposed labeling for its generic Zepbound® product (ANDA No. 220664), which allegedly "instructs and encourages improving weight management" using the claimed regimen Compl. ¶¶179-182

U.S. Patent No. 12,616,740 - "METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY"

  • Technology Synopsis: This patent claims methods for treating type 2 diabetes (claim 1) and obesity (claim 6) by administering tirzepatide in a specific dose-escalation regimen. The regimen involves a 2.5 mg starting dose for four weeks, followed by 2.5 mg incremental increases to a maintenance dose of 5, 10, or 15 mg Compl. ¶¶199 Compl. ¶201
  • Asserted Claims: At least independent claims 1 and 6 Compl. ¶200 Compl. ¶202
  • Accused Features: Defendants' proposed labeling for its generic Mounjaro® (ANDA No. 220663) and Zepbound® (ANDA No. 220664) products, which allegedly instructs and encourages the claimed treatment regimens Compl. ¶¶197-202

U.S. Patent No. 12,629,404 - "GIP/GLP1 AGONIST COMPOSITIONS"

  • Technology Synopsis: This patent claims a pharmaceutical composition that is free of preservatives and comprises tirzepatide, a specific range of NaCl, and has a pH of 6.5 to 7.5 Compl. ¶221
  • Asserted Claims: At least independent claim 1 Compl. ¶222
  • Accused Features: The formulation of Defendants' proposed generic Mounjaro® and Zepbound® products Compl. ¶222

III. The Accused Instrumentality

Product Identification

  • The accused instrumentalities are Defendants' "Proposed ANDA Products" submitted under ANDA Nos. 220663 and 220664 Compl. ¶1 These are proposed generic versions of Lilly's Mounjaro® and Zepbound® products, which contain the active pharmaceutical ingredient tirzepatide Compl. ¶48

Functionality and Market Context

  • The Proposed ANDA Products are intended to be generic equivalents of Lilly's brand-name drugs, offered in various strengths in both autoinjectors and vials Compl. ¶1 The complaint alleges that these products will be marketed for the same indications as Mounjaro® and Zepbound®, including to improve glycemic control in type 2 diabetes, for chronic weight management, and to treat obstructive sleep apnea Compl. ¶1 The filing of the ANDAs containing Paragraph IV certifications is alleged to be a statutory act of infringement under 35 U.S.C. § 271(e)(2) to enable the marketing of these products prior to the expiration of the Asserted Patents Compl. ¶¶60-61 The complaint provides a chemical structure diagram of tirzepatide to allege it meets the structural formula of claim 1 of the '780 Patent Compl. ¶55

IV. Analysis of Infringement Allegations

'780 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound of Formula: YX1EGTFTSDYSIX2LDKIAQKAX3VQWLIAGGPSSGAPPPS; The Proposed ANDA Products contain tirzepatide, which is alleged to be a compound with the claimed structural formula. ¶54 col. 41:42-43
wherein X1 is Aib; X2 is Aib; The proposed products contain tirzepatide, which is alleged to have Aib at positions X1 and X2. ¶54 col. 41:44
K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(yGlu)a-CO-(CH2)b-CO2H wherein a is 1 to 2 and b is 10 to 20; The proposed products contain tirzepatide, which is alleged to have the claimed chemical modification at position 20. ¶54 col. 41:45-50
X3 is Phe or 1-Nal; and The proposed products contain tirzepatide, which is alleged to have a corresponding structure at position X3. ¶54 col. 41:50
the C-terminal amino acid is optionally amidated as a C-terminal primary amide (SEQ ID NO: 11), or a pharmaceutically acceptable salt thereof. The proposed products contain tirzepatide, which is alleged to have a C-terminal primary amide, or a salt thereof. ¶54 col. 41:51-53
  • Identified Points of Contention:
    • Structural Scope: The primary question is factual: does the tirzepatide in Defendants' Proposed ANDA Products have the exact chemical structure, including all specified modifications and non-natural amino acids, as claimed in the '780 Patent? The complaint's inclusion of a structural diagram suggests a direct allegation of structural identity Compl. ¶55
    • Salt Form: The analysis may raise the question of whether the specific salt form of tirzepatide used by Defendants, if different from Plaintiff's, falls within the scope of "a pharmaceutically acceptable salt thereof" as construed in light of the patent's specification.

'820 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof; The Proposed ANDA Products are alleged to be pharmaceutical compositions that contain tirzepatide. ¶72 col. 1:11-12
NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; The Proposed ANDA Products are alleged to contain NaCl within this specified concentration range. ¶72 col. 1:35-37
and dibasic sodium phosphate. The Proposed ANDA Products are alleged to contain the claimed buffering agent. ¶72 col. 1:33-34
  • Identified Points of Contention:
    • Formulation Match: The central question is factual and quantitative: does the formulation of Defendants' Proposed ANDA Products contain all three claimed components (tirzepatide, NaCl, dibasic sodium phosphate), with the NaCl concentration falling strictly within the 6.2 mg/mL to 9.5 mg/mL range?
    • Scope of "dibasic sodium phosphate": A potential point of contention could be the specific form of dibasic sodium phosphate used. The analysis raises the question of whether the claim term covers all hydrated and anhydrous forms, or if its scope is limited by specific embodiments in the specification (e.g., dibasic sodium phosphate heptahydrate) Compl. ¶21 US 11,357,820 B2, Table 3

V. Key Claim Terms for Construction

  • The Term: "pharmaceutically acceptable salt thereof" (from claim 1 of the '780 Patent)

  • Context and Importance: This term is critical because infringement of a compound claim can hinge on the specific form of the active ingredient. If Defendants' proposed product uses a different salt form of tirzepatide than Plaintiff's commercial product, or uses the free base, the construction of this term will determine whether that alternative form is covered by the claim.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The patent specification may provide a broad, conventional definition, such as any salt that retains the biological effectiveness of the free acid/base and is not biologically or otherwise undesirable.
    • Evidence for a Narrower Interpretation: The specification for the related '820 Patent explicitly notes that an embodiment is a "tirzepatide trifluoroacetate salt" US 11,357,820 B2, col. 3:35-37 Parties may argue that if only specific salts are exemplified across the patent family, the scope of "acceptable salt" should be construed narrowly.

  • The Term: "dibasic sodium phosphate" (from claim 1 of the '820 Patent)

  • Context and Importance: Practitioners may focus on this term because different hydrated forms of a salt can have different physical properties, which might be relevant to formulation stability or manufacturing. The complaint itself refers to "sodium phosphate dibasic heptahydrate" in Lilly's approved product Compl. ¶21, raising the question of whether the claim is limited to that specific form.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The plain language of the claim is not limited to any particular hydrate, suggesting the term should be given its ordinary meaning covering all forms, including anhydrous and various hydrates.
    • Evidence for a Narrower Interpretation: The '820 Patent's specification includes a table with a formulation containing "Sodium phosphate dibasic 7H2O" US 11,357,820 B2, Table 3 A party could argue that this specific example limits the scope of the broader claim term to the heptahydrate form.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Defendants will induce infringement of the various method-of-use patents ('623, '987, '382, '755, '758, '740) Compl. ¶¶97 Compl. ¶115 Compl. ¶135 The allegations are based on the assertion that Defendants' proposed product labeling for the generic drugs will instruct and encourage healthcare providers and patients to administer the drug in accordance with the patented methods, such as for specific indications (e.g., obesity) or using claimed dose-escalation schedules Compl. ¶¶98 Compl. ¶116 Compl. ¶136
  • Willful Infringement: The complaint alleges facts that may support a claim for enhanced damages under 35 U.S.C. § 285. It asserts that Defendants had pre-suit knowledge of the asserted patents, at a minimum, because the patents are listed in the FDA's Orange Book and were included in Defendants' own Notice Letters Compl. ¶¶63 Compl. ¶80 The complaint further alleges that Defendants "have no reasonable basis to believe" their proposed products would not infringe, which is standard language supporting a claim of willfulness Compl. ¶¶59 Compl. ¶76

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of compositional identity: On the product claims, the case will depend on whether the chemical structure and formulation of Defendants' proposed generic products are factually identical to the compounds and compositions defined by the claims of patents like the '780 and '820. This will involve a direct comparison of the generic product's characteristics against the specific limitations of the patent claims.
  • A second key question will be one of induced infringement and labeling: For the method-of-use patents, the dispute will likely turn on the content of Defendants' proposed product labels. The court will need to determine if the instructions and indications on the labels will inevitably lead physicians and patients to practice the patented methods of treatment and dosing, or if Defendants can successfully "carve out" the patented uses from their labels to avoid liability for inducement.
  • A third, overarching issue will be the question of patent validity: While not detailed in the complaint, Defendants' Paragraph IV certifications inherently assert that the patents-in-suit are invalid. A core component of the litigation will therefore be Defendants' affirmative defense and counterclaim that Lilly's patents, covering the fundamental compound, its formulation, and various methods of use, are invalid over the prior art or for failure to meet other statutory requirements.
Loading Complaint